StemBioSys Announces Launch of CELLvo™ Atrial Cardiomyocyte, a Technological Leap Forward in Cardiotoxicity Screening
Developed in collaboration with REPROCELL, CELLvo™ Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells SAN ANTONIO, ...